Heparin

• 

  Subject Areas on Research

  • "Hot" unstable angina--is it worse than subacute unstable angina? Results from the GUARANTEE Registry. 
  • 2-O, 3-O-desulfated heparin inhibits neutrophil elastase-induced HMGB-1 secretion and airway inflammation. 
  • A Brazilian perspective for the use of bovine heparin in open heart surgery. 
  • A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. 
  • A beta-adrenergic receptor kinase-like enzyme is involved in olfactory signal termination. 
  • A change in anticoagulation monitoring improves safety, reduces transfusion, and reduces costs in infants on cardiopulmonary bypass. 
  • A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. 
  • A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. 
  • A comparison of tibial artery bypass performed with heparin-bonded expanded polytetrafluoroethylene and great saphenous vein to treat critical limb ischemia. 
  • A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. 
  • A diagnosis of heparin-induced thrombocytopenia with combined clinical and laboratory methods in cardiothoracic surgical intensive care unit patients. 
  • A follow-up survey of clinical practices for the use of heparin, warfarin, and aspirin. 
  • A marriage of enhancement: fibrinolysis and conjunctive therapy. 
  • A mouse model for heparin-induced thrombocytopenia. 
  • A multicenter study of anticoagulation parameters when using heparin and warfarin. 
  • A mutation in the largest subunit of RNA polymerase II alters RNA chain elongation in vitro. 
  • A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery. 
  • A novel method to assess platelet inhibition by eptifibatide with thrombelastograph. 
  • A perspective on trials comparing enoxaparin and unfractionated heparin in the treatment of non-ST-elevation acute coronary syndromes. 
  • A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. 
  • A prospective study measuring the development of antibodies against platelet factor 4-heparin in healthy males after exposure to heparins. 
  • A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. 
  • A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. 
  • A randomized trial of low-dose heparin and intermittent pneumatic calf compression for the prevention of deep venous thrombosis after gynecologic oncology surgery. 
  • A risk score to predict bleeding in patients with acute coronary syndromes. 
  • A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. 
  • ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT? 
  • ATP-regulated activity of the plasmin-streptokinase complex: a novel mechanism involving phosphorylation of streptokinase. 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. 
  • Absolute and relative truth in clinical trials. 
  • Accidental heparinization in the newborn: a case report and brief review of the literature. 
  • Acidic fibroblast growth factor enhances peripheral nerve regeneration in vivo. 
  • Acquired thrombotic risk factors in the critical care setting. 
  • Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial. 
  • Activated clotting time systems vary in precision and bias and are not interchangeable when following heparin management protocols during cardiopulmonary bypass. 
  • Activated clotting times, heparin responses, and antithrombin: have we been wrong all these years? 
  • Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. 
  • Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST-segment elevation acute coronary syndromes treated with unfractionated heparin. 
  • Activation-dependent conformational changes in {beta}-arrestin 2. 
  • Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. 
  • Acute management of intracranial hemorrhage in patients receiving thrombolytic therapy: case reports. 
  • Acute reduction of lipoprotein(a) by tissue-type plasminogen activator. 
  • Adeno-associated viral vectors based on serotype 3b use components of the fibroblast growth factor receptor signaling complex for efficient transduction. 
  • Adjunctive use of the Rinspiration system for fluidic thrombectomy during primary angioplasty: the Rinspiration international registry. 
  • Adult extracorporeal membrane oxygenation: an international survey of transfusion and anticoagulation techniques. 
  • Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Advances in antithrombotic therapy in acute myocardial infarction: the ExTRACT-TIMI 25 and OASIS-6 Trials. 
  • Adverse events in the use of HeartMate vented electric and Novacor left ventricular assist devices: comparing apples and oranges. 
  • Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. 
  • American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. 
  • An analysis of the Association of Society of Chest Pain Centers Accreditation to American College of Cardiology/American Heart Association non-ST-segment elevation myocardial infarction guideline adherence. 
  • An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age. 
  • An automated strategy for bedside aPTT determination and unfractionated heparin infusion adjustment in acute coronary syndromes: insights from PARAGON A. 
  • An in vitro neurite-promoting antigen functions in axonal regeneration in vivo. 
  • An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. 
  • An updated comprehensive meta-analysis of bivalirudin vs heparin use in primary percutaneous coronary intervention. 
  • Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. 
  • Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. 
  • Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. 
  • Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. 
  • Antibodies to platelet factor 4/heparin are associated with elevated endothelial cell activation markers in patients with acute coronary ischemic syndromes. 
  • Anticoagulant Use Among Patients With End-Stage Renal Disease Undergoing Percutaneous Coronary Intervention: An Analysis From the National Cardiovascular Data Registry. 
  • Anticoagulant therapy during cardiopulmonary bypass. 
  • Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. 
  • Anticoagulant therapy in unstable angina. 
  • Anticoagulation and reversal paradigms: is too much of a good thing bad? 
  • Anticoagulation in acute cardiac care in patients with chronic kidney disease. 
  • Anticoagulation in coronary intervention. 
  • Anticoagulation management associated with extracorporeal circulation. 
  • Anticoagulation monitoring during pediatric extracorporeal membrane oxygenation. 
  • Anticoagulation techniques in apheresis: from heparin to citrate and beyond. 
  • Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. 
  • Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. 
  • Antimetastatic potential of PAI-1-specific RNA aptamers. 
  • Antiphospholipid syndrome and cardiac surgery: management of anticoagulation in two patients. 
  • Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? 
  • Antithrombin III, a serpin family protease inhibitor, is a major heparin binding protein in porcine aqueous humor. 
  • Antithrombin alternatives in STEMI. 
  • Antithrombin deficiency in special clinical syndromes--Part II: cardiovascular surgery. 
  • Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. 
  • Antithrombotic strategy in non-ST-segment elevation myocardial infarction patients undergoing percutaneous coronary intervention: insights from the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) Registry. 
  • Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician. 
  • Antithrombotic therapy in patients undergoing coronary angioplasty. 
  • Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. 
  • Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. 
  • Argatroban for anticoagulation during cardiopulmonary bypass in an infant. 
  • Assessments of thrombogenicity by three in vitro techniques. Student Research Award in the Undergraduate, Master Candidate, or Health Science Degree Candidate Category, 21st annual meeting of the Society for Biomaterials, San Francisco, CA, March 18-22, 1995. 
  • Association between platelet receptor occupancy after eptifibatide (integrilin) therapy and patency, myocardial perfusion, and ST-segment resolution among patients with ST-segment-elevation myocardial infarction: an INTEGRITI (Integrilin and Tenecteplase in Acute Myocardial Infarction) substudy. 
  • Atomic description of the immune complex involved in heparin-induced thrombocytopenia. 
  • Attenuation of rebound ischemia after discontinuation of heparin therapy by glycoprotein IIb/IIIa inhibition with eptifibatide in patients with acute coronary syndromes: observations from the platelet IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial. 
  • Augmentation of coronary collateral blood flow in acute myocardial infarction. 
  • Autocrine-paracrine mechanisms of vascular myocytes in systemic hypertension. 
  • Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. 
  • Bilateral posterior fossa subdural haematomas secondary to anticoagulant therapy. 
  • Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. 
  • Bivalirudin for patients with acute coronary syndromes. 
  • Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. 
  • Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. 
  • Bivalirudin provides rapid, effective, and reliable anticoagulation during off-pump coronary revascularization: results of the "EVOLUTION OFF" trial. 
  • Bivalirudin versus unfractionated heparin in percutaneous coronary interventions of patients having received initial fondaparinux treatment: a propensity matched study. 
  • Bivalirudin with a post-procedure infusion versus heparin monotherapy for the prevention of stent thrombosis. 
  • Bivalirudin: a review of the pharmacology and clinical application. 
  • Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. 
  • Bleeding in acute coronary syndromes. 
  • Bleeding risk comparing targeted low-dose heparin with bivalirudin in patients undergoing percutaneous coronary intervention: results from a propensity score-matched analysis of the Evaluation of Drug-Eluting Stents and Ischemic Events (EVENT) registry. 
  • Blunt vascular injuries of the head and neck: is heparinization necessary? 
  • Bone density changes in women who receive thromboprophylaxis in pregnancy. 
  • Brachial artery reconstruction using the heparin-bonded Sundt shunt. 
  • Canadian Consensus Conference on Coronary Thrombolysis--1994 update. 
  • Canadian-American differences in the management of acute coronary syndromes in the GUSTO IIb trial: one-year follow-up of patients without ST-segment elevation. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) II Investigators. 
  • Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. 
  • Cardiopulmonary Bypass Strategy for a Cyanotic Child With Hemoglobin SC Disease. 
  • Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. 
  • Cell- and heparin-binding domains of the hexabrachion arm identified by tenascin expression proteins. 
  • Changing systems for measuring activated clotting times: impact on the clinical practice of heparin anticoagulation during cardiac surgery. 
  • Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial. 
  • Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. 
  • Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes. 
  • Characterization of the murine BEK fibroblast growth factor (FGF) receptor: activation by three members of the FGF family and requirement for heparin. 
  • Chemokines have diverse abilities to form solid phase gradients. 
  • Chemotaxis of mononuclear leukocytes. 
  • Clinical Crossroads: a 36-year-old woman recuperating from stroke. 
  • Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. 
  • Clinical outcomes of bivalirudin for ischemic heart disease. 
  • Clinical outcomes with unfractionated heparin or low-molecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. 
  • Clinical practice. Heparin-induced thrombocytopenia. 
  • Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. 
  • Combination of aptamer and drug for reversible anticoagulation in cardiopulmonary bypass. 
  • Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. 
  • Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. 
  • Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. 
  • Comparison of ancrod and heparin as anticoagulants following endarterectomy in the dog. 
  • Comparison of benefits and complications of hirudin versus heparin for patients with acute coronary syndromes undergoing early percutaneous coronary intervention. 
  • Comparison of bivalirudin versus heparin(s) during percutaneous coronary interventions in patients receiving prasugrel: a propensity-matched study. 
  • Comparison of effectiveness of enoxaparin versus unfractionated heparin to reduce silent and clinically apparent acute myocardial infarction in patients presenting with non-ST-segment elevation acute coronary syndrome. 
  • Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. 
  • Complement factor H variant increases the risk of age-related macular degeneration. 
  • Complete atrioventricular block complicating inferior wall acute myocardial infarction treated with reperfusion therapy. TAMI Study Group. 
  • Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. 
  • Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. 
  • Conditions influencing the interaction of asialo von Willebrand factor with human platelets--the effects of external ionized calcium concentration and the role of arachidonate pathway. 
  • Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. 
  • Contraceptive Management for Women Who Are at High Risk of Thrombosis. 
  • Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. 
  • Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library. 
  • Coronary intervention and glycoprotein IIb/IIIa integrin blockade. 
  • Coronary revascularization surgery after myocardial infarction: impact of bypass surgery on survival after thrombolysis. GUSTO Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Correlation Among Antifactor Xa, Activated Partial Thromboplastin Time, and Heparin Dose and Association with Pediatric Extracorporeal Membrane Oxygenation Complications. 
  • Cortical granule exocytosis is triggered by different thresholds of calcium during fertilisation in sea urchin eggs. 
  • Cost-effectiveness of deep venous thrombosis prophylaxis in gynecologic oncology surgery. 
  • Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding. 
  • Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis. 
  • Critical Influence of Cosolutes and Surfaces on the Assembly of Serpin-Derived Amyloid Fibrils. 
  • Critical role for mouse marginal zone B cells in PF4/heparin antibody production. 
  • Cross-dressing the virion: the transcapsidation of adeno-associated virus serotypes functionally defines subgroups. 
  • Crustacean peptide and peptide-like pheromones and kairomones. 
  • Current perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategies. 
  • Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: experience from GUSTO-IIb. Global Utilization of Strategies for Total Occlusion. 
  • Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. 
  • Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. 
  • Design and rationale for the Minimizing Adverse haemorrhagic events by TRansradial access site and systemic Implementation of angioX program. 
  • Determinants of PF4/heparin immunogenicity. 
  • Determination of high density lipoprotein-cholesterol in stored human plasma. 
  • Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100. 
  • Development and evaluation of a pliable biological valved conduit. Part I: Preparation, biochemical properties, and histological findings. 
  • Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. 
  • Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Diagnosing heparin-induced thrombocytopenia in cardiac surgical patients: not as easy as you think. 
  • Diagnosis and management of heparin-induced thrombocytopenia. 
  • Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. 
  • Direct Thrombin Inhibition During Left-Sided Catheter Ablation: More Than Just an Alternative? 
  • Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. 
  • Direct thrombin inhibitors: alternatives to heparin. 
  • Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures. 
  • Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). 
  • Disseminated intravascular coagulation (DIC): an approach. 
  • Disseminated intravascular coagulation: a dermatologic disease. 
  • Disseminated intravascular coagulation: a reappraisal. 
  • Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4. 
  • Doing the right things and doing them the right way: association between hospital guideline adherence, dosing safety, and outcomes among patients with acute coronary syndrome. 
  • Dosing and administration of ReoPro (c7E3 Fab). 
  • Drug-induced bone disease. 
  • Dry electrolyte-balanced heparinized syringes evaluated for determining ionized calcium and other electrolytes in whole blood. 
  • Dual-function injectable angiogenic biomaterial for the repair of brain tissue following stroke. 
  • Dynamic antibody-binding properties in the pathogenesis of HIT. 
  • Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia. 
  • Dynamic prognostication in non-ST-elevation acute coronary syndromes: insights from GUSTO-IIb and PURSUIT. 
  • Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. 
  • Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. 
  • Early thrombus formation on heparin-bonded pulmonary artery catheters in patients receiving epsilon aminocaproic acid. 
  • Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. 
  • Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarction]. 
  • Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. 
  • Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: results from the EPILOG randomized trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Economic assessment of thrombocytopenia: CATCH Registry. 
  • Economic evaluation of bivalirudin with or without glycoprotein IIb/IIIa inhibition versus heparin with routine glycoprotein IIb/IIIa inhibition for early invasive management of acute coronary syndromes. 
  • Economic impact of new interventional therapies: are we asking the right questions? 
  • Effect of Post-Primary Percutaneous Coronary Intervention Bivalirudin Infusion on Acute Stent Thrombosis: Meta-Analysis of Randomized Controlled Trials. 
  • Effect of age on outcome with primary angioplasty versus thrombolysis. 
  • Effect of colistin on phospholipid-based activated partial thromboplastin time clotting assay results in patients receiving concomitant heparin therapy. 
  • Effect of combined anticoagulation using heparin and bivalirudin on the hemostatic and inflammatory responses to cardiopulmonary bypass in the rat. 
  • Effect of heparin administration on metabolomic profiles in samples obtained during cardiac catheterization. 
  • Effect of heparin on vitamin A induced hyperlipidemia in rats. 
  • Effect of hirudin vs heparin on haemostatic activity in patients with acute coronary syndromes; the GUSTO-IIb haemostasis substudy. 
  • Effect of post-primary percutaneous coronary intervention bivalirudin infusion on net adverse clinical events and mortality: A comprehensive pairwise and network meta-analysis of randomized controlled trials. 
  • Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. 
  • Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan. 
  • Effects of blended lithium-zinc heparin on ionized calcium and general clinical chemistry tests. 
  • Effects of enoxaparin, standard heparin, and streptokinase on the patency of anastomoses in severely crushed arteries. 
  • Effects of estrogen/progestin agents on plasma retinoids and chylomicron remnant metabolism. 
  • Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. 
  • Effects of heparin and cardiac catheterization on serum lipoprotein and triglyceride levels. 
  • Effects of inherited thrombophilic mutations in an adolescent with antiphospholipid syndrome and systemic lupus erythematosus. 
  • Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial. 
  • Effects of local heparin administration on coronary thrombin activity during percutaneous transluminal coronary angioplasty. 
  • Effects of pre-analytical variables on the anti-activated factor X chromogenic assay when monitoring unfractionated heparin and low molecular weight heparin anticoagulation. 
  • Effects of protamine on histamine release from human lung. 
  • Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. 
  • Efficacy and safety of early versus late initiation of warfarin during heparin therapy in acute thromboembolism. 
  • Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 
  • Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. 
  • Efficacy and safety of minimal dose (< or =1,000 units) unfractionated heparin with abciximab in percutaneous coronary intervention. 
  • Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. 
  • Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. 
  • Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. 
  • Efficacy of saline vs heparin in maintaining 24-gauge intermittent intravenous catheters in a rabbit model. 
  • Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. 
  • Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. 
  • Endothelial cell-conditioned medium downregulates smooth muscle contractile protein expression. 
  • Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. 
  • Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events). 
  • Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial. 
  • Enoxaparin vs unfractionated heparin in acute coronary syndrome. 
  • Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. 
  • Epidermal growth factor (EGF) receptor-dependent ERK activation by G protein-coupled receptors: a co-culture system for identifying intermediates upstream and downstream of heparin-binding EGF shedding. 
  • Epidurals in patients receiving thromboprophylaxis with unfractionated heparin three times a day: the value of activated partial thromboplastin time testing. 
  • Etiology and assessment of hypercoagulability with lessons from heparin-induced thrombocytopenia. 
  • Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. 
  • Evaluation of a rapid and automated heparin-induced thrombocytopenia immunoassay. 
  • Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia. 
  • Evaluation of preanalytical variables associated with measurement of prothrombin fragment 1.2. 
  • Evaluation of the thrombogenecity of microvascular prosthesis by in vivo microscopy. 
  • Evidence for the involvement of platelet glycoproteins other than GP Ib in heparin-associated thrombocytopenia and thrombosis. 
  • Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: a review of pharmacologic and clinical differences and applications in patients with cancer. 
  • Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. 
  • Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. 
  • Extensive thrombus prior to elective percutaneous coronary intervention. 
  • Facilitated percutaneous coronary intervention versus primary percutaneous coronary intervention: design and rationale of the Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events (FINESSE) trial. 
  • Factor XII deficiency and cardiopulmonary bypass: use of a novel modification of the activated clotting time to monitor anticoagulation. 
  • Failure of adjuvant heparin to reduce myocardial ischemia in the early treatment of patients with unstable angina. 
  • Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. 
  • Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis. 
  • Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC Trial). 
  • Fibrinolysis vs disseminated intravascular coagulation. 
  • First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. 
  • First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS Trial. 
  • Fluorescent low density lipoprotein for observation of dynamics of individual receptor complexes on cultured human fibroblasts. 
  • Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. 
  • Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): a randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes initially treated with fondaparinux. 
  • Frequency and Effects of Excess Dosing of Anticoagulants in Patients ≤55 Years With Acute Myocardial Infarction Who Underwent Percutaneous Coronary Intervention (from the VIRGO Study). 
  • Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. 
  • Further characterization of a factor from endotoxin-treated serum which releases histamine and heparin from mast cells. 
  • Future alternatives to heparin: low-molecular-weight heparin and hirudin. 
  • Gastrointestinal bleeding in patients with acute coronary syndromes: incidence, predictors, and clinical implications: analysis from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Gender Differences in Associations Between Intraprocedural Thrombotic Events During Percutaneous Coronary Intervention and Adverse Outcomes. 
  • Gender and acute myocardial infarction: is there a different response to thrombolysis? 
  • Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. 
  • Graded exercise testing following thrombolytic therapy for acute myocardial infarction: the importance of timing and infarct location. TPAT Study Group. 
  • HIT and run: heparin's unusual immune response. 
  • HIT happens: diagnosing and evaluating the patient with heparin-induced thrombocytopenia. 
  • Heart rate variability assessment early after acute myocardial infarction. Pathophysiological and prognostic correlates. GUSTO ECG Substudy Investigators. Global Utilization of Streptokinase and TPA for Occluded Arteries. 
  • Hematologic and surgical management of the dental patient with plasminogen activator deficiency. 
  • Hematologic changes occurring with cardiac catheterization. 
  • Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. 
  • Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. 
  • Heparin anticoagulation in patients undergoing off-pump and on-pump coronary bypass surgery. 
  • Heparin binding EGF is necessary for vasospastic response to endothelin. 
  • Heparin bonding increases patency of long microvascular prostheses. 
  • Heparin coating of vascular prostheses reduces thromboemboli. 
  • Heparin dosing and outcome in acute coronary syndromes: the GUSTO-IIb experience. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages. 
  • Heparin in acute coronary disease--requiem for a heavyweight? 
  • Heparin management in acute myocardial infarction (AMI). 
  • Heparin mimicking polymer promotes myogenic differentiation of muscle progenitor cells. 
  • Heparin modifies the immunogenicity of positively charged proteins. 
  • Heparin monotherapy or bivalirudin during percutaneous coronary intervention in patients with non-ST-segment-elevation acute coronary syndromes or stable ischemic heart disease: results from the Evaluation of Drug-Eluting Stents and Ischemic Events registry. 
  • Heparin neutralization by recombinant platelet factor 4 and protamine. 
  • Heparin neutralization with methylene blue, hexadimethrine, or vancomycin after cardiopulmonary bypass. 
  • Heparin oligosaccharides enhance tissue-type plasminogen activator: a correlation between oligosaccharide length and stimulation of plasminogen activation. 
  • Heparin resistance and antithrombin: should it still be called heparin resistance? 
  • Heparin therapy during cardiopulmonary bypass in children requires ongoing quality control. 
  • Heparin use for diagnostic cardiac catheterization with a radial artery approach: An international survey of practice patterns. 
  • Heparin versus hirudin for acute coronary syndromes. 
  • Heparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists. 
  • Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. 
  • Heparin-associated thrombocytopenia and thrombosis: a serious clinical problem and potential solution. 
  • Heparin-coated stents do not protect cancer patients from cardiac complications after noncardiac surgery. 
  • Heparin-dependent platelet factor 4 antibodies and the impact of renal function on clinical outcomes: a retrospective study in hospitalized patients. 
  • Heparin-induced decrease in circulating antithrombin-III. 
  • Heparin-induced thrombocytopenia and cardiac surgery. 
  • Heparin-induced thrombocytopenia and thrombosis. 
  • Heparin-induced thrombocytopenia in cancer. 
  • Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients. 
  • Heparin-induced thrombocytopenia in the pediatric intensive care unit population. 
  • Heparin-induced thrombocytopenia, a prothrombotic disease. 
  • Heparin-induced thrombocytopenia. 
  • Heparin-induced thrombocytopenia. 
  • Heparin-induced thrombocytopenia. 
  • Heparin-induced thrombocytopenia. 
  • Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. 
  • Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. 
  • Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. 
  • Heparin-induced thrombocytopenia: clinical presentations and therapeutic management. 
  • Heparin-induced thrombocytopenia: research and clinical updates. 
  • Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. 
  • Heparin-mediated hypotension associated with cardiac surgery. 
  • Heparinase I (neutralase) reversal of systemic anticoagulation. 
  • Hierarchy of risk based on history and location of prior myocardial infarction in the thrombolytic era. GUSTO-I Investigators. 
  • High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. 
  • High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. 
  • Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Hospital variability in use of anticoagulant strategies during acute myocardial infarction treated with an early invasive strategy. 
  • How I treat catastrophic thrombotic syndromes. 
  • Human skin chymotrypsin-like proteinase chymase. Subcellular localization to mast cell granules and interaction with heparin and other glycosaminoglycans. 
  • Hypercoagulability affecting early vein graft patency does not exist after off-pump coronary artery bypass. 
  • Identification of a glycosaminoglycan-binding site in chemokine macrophage inflammatory protein-1alpha. 
  • Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. 
  • Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. 
  • Immune pathogenesis of heparin-induced thrombocytopenia. 
  • Impact of an aggressive invasive catheterization and revascularization strategy on mortality in patients with cardiogenic shock in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial. An observational study. 
  • Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. 
  • Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy. 
  • Impact of congestive heart failure in patients with non-ST-segment elevation acute coronary syndromes. 
  • Impact of gender and antithrombin strategy on early and late clinical outcomes in patients with non-ST-elevation acute coronary syndromes (from the ACUITY trial). 
  • Impact of home warfarin use on treatment patterns and bleeding complications for patients with non-ST-segment elevation acute coronary syndromes: observations from the CRUSADE quality improvement initiative. 
  • Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. 
  • Impact of tissue plasminogen activator and heparin versus heparin alone on quantitative coronary angiographic findings in myocardial infarction. The Toronto Tissue Plasminogen Activator Trial Study Group. 
  • Improved microsurgical anastomotic patency with low molecular weight heparin. 
  • In-vitro evaluation of anti-factor IXa aptamer on thrombin generation, clotting time, and viscoelastometry. 
  • Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue Plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. 
  • Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. 
  • Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. 
  • Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis. 
  • Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. 
  • Increased anticoagulation during cardiopulmonary bypass by aprotinin. 
  • Increased expression of fibroblast growth factors in a rabbit skeletal muscle model of exercise conditioning. 
  • Inference on treatment effects from a randomized clinical trial in the presence of premature treatment discontinuation: the SYNERGY trial. 
  • Influence of apolipoprotein E on soluble and heparin-immobilized hepatic lipase. 
  • Influence of clinical trial participation on subsequent antithrombin use. 
  • Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. 
  • Influence of heparin and isoproterenol on ventilation and perfusion following pulmonary embolism. 
  • Influence of hypothermic cardiopulmonary bypass on atrial natriuretic factor levels. 
  • Influence of sample collection and storage on the detection of platelet factor 4-heparin antibodies. 
  • Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Inhibition of beta-adrenergic receptor kinase prevents rapid homologous desensitization of beta 2-adrenergic receptors. 
  • Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin. 
  • Inhibition of the beta-adrenergic receptor kinase by polyanions. 
  • Initial experience with factor-Xa inhibition in percutaneous coronary intervention: the XaNADU-PCI Pilot. 
  • Interactions between heparins, glycoprotein IIb/IIIa antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE). 
  • Interference of thrombin in immunological assays for hirudin specific antibodies. 
  • Intracranial hemorrhage after coronary thrombolysis with tissue plasminogen activator. 
  • Intraluminal thrombus in facilitated versus primary percutaneous coronary intervention: an angiographic substudy of the ASSENT-4 PCI (Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention) trial. 
  • Intravascular coagulation--a source of possible error in carbon-clearance determinations. 
  • Intravenous recombinant tissue-type plasminogen activator in patients with unstable angina pectoris. Results of a placebo-controlled, randomized trial. 
  • Invited commentary. 
  • Ionic modulation of the effects of heparin on plasminogen activation by tissue plasminogen activator: the effects of ionic strength, divalent cations, and chloride. 
  • Ipsilateral internal carotid artery redissection on anticoagulation. 
  • Is streptokinase safe during menses? 
  • Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis? 
  • Isolation and characterization of an acquired antithrombin antibody. 
  • Kinetic analysis of the effects of glycosaminoglycans and lipoproteins on urokinase-mediated plasminogen activation. 
  • Kinetic analysis of the effects of heparin and lipoproteins on tissue plasminogen activator mediated plasminogen activation. 
  • Kinetics of elimination of antithrombin III concentrate in heparinized patients. 
  • Lesion-directed administration of alteplase with intracoronary heparin in patients with unstable angina and coronary thrombus undergoing angioplasty. 
  • Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. 
  • Local delivery of heparin post-PTCA: a multicenter randomized pilot study. 
  • Long-term mortality of patients with acute myocardial infarction in the United States and Canada: comparison of patients enrolled in Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO)-I. 
  • Low dose heparin therapy: in vitro verification of antithrombotic effect. 
  • Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study. 
  • Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. 
  • Low-molecular-weight heparin compared with unfractionated heparin for patients with non-ST-segment elevation acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE initiative. 
  • Low-molecular-weight heparin versus unfractionated heparin for unstable coronary disease. 
  • Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. 
  • Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. 
  • Lymphocyte responses to purified ragweed allergens in vitro. I. Proliferative responses in normal, newborn, agammaglobulinemic, and atopic subjects. 
  • Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time. 
  • Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. 
  • Mast cell-derived particles deliver peripheral signals to remote lymph nodes. 
  • Mechanism of Aspergillus-induced microangiopathic hemolytic anemia. 
  • Medical records and quality of care in acute coronary syndromes: results from CRUSADE. 
  • Meta-Analysis of Effects of Bivalirudin Versus Heparin on Myocardial Ischemic and Bleeding Outcomes After Percutaneous Coronary Intervention. 
  • Meta-analysis comparing bivalirudin versus heparin monotherapy on ischemic and bleeding outcomes after percutaneous coronary intervention. 
  • Meta-analysis of multitreatment studies. 
  • Metabolic glycan labeling and chemoselective functionalization of native biomaterials. 
  • Minidose heparin therapy for vasculitis of atrophie blanche. 
  • Mitogenic and adhesive effects of tenascin-C on human hematopoietic cells are mediated by various functional domains. 
  • Mitral valvular interstitial cell responses to substrate stiffness depend on age and anatomic region. 
  • Mixed connective tissue disease with arterial thrombosis, antiphospholipid antibodies and heparin induced thrombocytopenia. 
  • Modest Associations Between Electronic Health Record Use and Acute Myocardial Infarction Quality of Care and Outcomes: Results From the National Cardiovascular Data Registry. 
  • Modifiable risk factors for vascular access site complications in the IMPACT II Trial of angioplasty with versus without eptifibatide. Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. 
  • Modulation of tissue plasminogen activator-catalyzed plasminogen activation by synthetic peptides derived from the amino-terminal heparin binding domain of fibronectin. 
  • Multicenter randomized trial and a systematic overview of lidocaine in acute myocardial infarction. 
  • Multicenter trial of desirudin for the prophylaxis of thrombosis: an alternative to heparin-based anticoagulation (DESIR-ABLE). 
  • Multicenter, dose-ranging study of efegatran sulfate versus heparin with thrombolysis for acute myocardial infarction: The Promotion of Reperfusion in Myocardial Infarction Evolution (PRIME) trial. 
  • Multiple pathways of rapid beta 2-adrenergic receptor desensitization. Delineation with specific inhibitors. 
  • Multivessel coronary artery disease: a key predictor of short-term prognosis after reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. 
  • New heparin dosing recommendations for patients with acute coronary syndromes. 
  • New treatment options for heparin-induced thrombocytopenia. 
  • Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline. 
  • Novel Immunoassay for Complement Activation by PF4/Heparin Complexes. 
  • Novel constructs for thrombin inhibition. 
  • Novel diagnostic assays for heparin-induced thrombocytopenia. 
  • Novel pharmacologic approaches to reduce bleeding. 
  • Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies. 
  • One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. 
  • Optical detection of macromolecular heparin via selective coextraction into thin polymeric films. 
  • Optical detection of polycations via polymer film-modified microtiter plates: response mechanism and bioanalytical applications. 
  • Optimization of a murine immunization model for study of PF4/heparin antibodies. 
  • Optimizing heparin compounds: a working construct for future antithrombotic drug development. 
  • Outcome of acute ST-segment elevation myocardial infarction in patients with prior coronary artery bypass surgery receiving thrombolytic therapy. 
  • Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. 
  • Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction Via Radial Access Anticoagulated With Bivalirudin Versus Heparin: A Report From the National Cardiovascular Data Registry. 
  • Outcomes in elderly patients with acute coronary syndromes randomized to enoxaparin vs. unfractionated heparin: results from the SYNERGY trial. 
  • Overview of randomized trials of intravenous heparin in patients with acute myocardial infarction treated with thrombolytic therapy. 
  • PF4/heparin complexes are T cell-dependent antigens. 
  • PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. 
  • Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. 
  • Pathogenesis of heparin-induced thrombocytopenia and thrombosis. 
  • Pathogenesis of heparin-induced thrombocytopenia. 
  • Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. 
  • Patients with non-ST-elevation acute coronary syndromes undergoing coronary artery bypass grafting in the modern era of antithrombotic therapy. 
  • Patients with prolonged ischemic chest pain and presumed-new left bundle branch block have heterogeneous outcomes depending on the presence of ST-segment changes. 
  • Pearls & Oy-sters: multiple ischemic strokes secondary to heparin-induced thrombocytopenia. 
  • Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens. 
  • Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 
  • Performance of a new, rapid, automated immunoassay for the detection of anti-platelet factor 4/heparin complex antibodies. 
  • Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). 
  • Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. 
  • Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims. 
  • Pharmacologic prophylaxis, postoperative INR, and risk of venous thromboembolism after hepatectomy. 
  • Pharmacomechanical thrombolysis of experimental pulmonary emboli. Rapid low-dose intraembolic therapy. 
  • Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. 
  • Plasmin-mediated proteolysis of vascular endothelial cell heparin releasable tissue factor pathway inhibitor. 
  • Platelet activation after stenting with heparin-coated versus noncoated stents. 
  • Platelet and monocyte antigenic complexes in the pathogenesis of heparin-induced thrombocytopenia (HIT). 
  • Platelet count in deep saturation diving. 
  • Platelet factor 4-heparin complexes trigger immune responses independently of the MyD88 pathway. 
  • Platelet factor 4/heparin antibodies in blood bank donors. 
  • Platelet factor 4/heparin antibody (IgG/M/A) in healthy subjects: a literature analysis of commercial immunoassay results. 
  • Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. 
  • Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway. 
  • Positive heparin-platelet factor 4 antibody complex and cardiac surgical outcomes. 
  • Post-operative heparin may not be required for transitioning patients with a HeartMate II left ventricular assist system to long-term warfarin therapy. 
  • Post-procedure heparin: boon or burden? 
  • Postoperative disseminated intravascular coagulation and fibrinolysis. 
  • Practice bulletin no. 123: thromboembolism in pregnancy. 
  • Predicting and treating coagulopathies after cardiopulmonary bypass in children. 
  • Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. 
  • Predictors of cardiogenic shock after thrombolytic therapy for acute myocardial infarction. 
  • Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization And Urgent Intervention Triage Strategy (ACUITY) substudy. 
  • Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. 
  • Preemptive use of bivalirudin for urgent on-pump coronary artery bypass grafting in patients with potential heparin-induced thrombocytopenia. 
  • Prehospital electrocardiograms (ECGs) do not improve the process of emergency department care in hospitals with higher usage of ECGs in non-ST-segment elevation myocardial infarction patients. 
  • Preoperative anti-PF4/heparin antibody level predicts adverse outcome after cardiac surgery. 
  • Preoperative low molecular weight heparin reduces heparin responsiveness during cardiac surgery. 
  • Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. 
  • Preventing Acute Radial Artery Occlusion: A Battle on Multiple Fronts. 
  • Prevention and Management of Thromboembolism in Pregnancy When Heparins Are Not an Option. 
  • Prevention and treatment of venous thromboembolism in pregnancy. 
  • Prevention of superficial wound separation with subcutaneous retention sutures. 
  • Prevention of venous thrombosis in microvascular surgery by transmural release of heparin from a polyanhydride polymer. 
  • Primary upper-extremity deep venous thrombosis. 
  • Production of a novel anticoagulant by neoplastic plasma cells: report of a case and review of the literature. 
  • Production of chemotactic peptides by neutrophil degradation of heparin cofactor II. 
  • Profiling heparin-chemokine interactions using synthetic tools. 
  • Prognostic importance of concomitant heparin with eptifibatide in acute coronary syndromes. PURSUIT Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. 
  • Prognostic modeling of individual patient risk and mortality impact of ischemic and hemorrhagic complications: assessment from the Acute Catheterization and Urgent Intervention Triage Strategy trial. 
  • Prognostic significance of precordial ST segment depression during inferior myocardial infarction in the thrombolytic era: results in 16,521 patients. 
  • Prognostic value of angiographic lesion complexity in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the acute catheterization and urgent intervention triage strategy trial). 
  • Promise of combined low-molecular-weight heparin and platelet glycoprotein IIb/IIIa inhibition: results from Platelet IIb/IIIa Antagonist for the Reduction of Acute coronary syndrome events in a Global Organization Network B (PARAGON B). 
  • Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. 
  • Prophylaxis of thromboembolism. 
  • Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. 
  • Prospective comparison of the HEP score and 4Ts score for the diagnosis of heparin-induced thrombocytopenia. 
  • Protamine is an antagonist of apelin receptor, and its activity is reversed by heparin. 
  • Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. 
  • Protamine reversal of heparin: a fishy practice? 
  • Protamine-induced immune thrombocytopenia. 
  • Protocol adherence when managing massive bleeding following complex cardiac surgery: a study design pilot. 
  • Provocative angiography in patients with gastrointestinal hemorrhage of obscure origin. 
  • Provocative mesenteric angiography for lower gastrointestinal hemorrhage: results from a single-institution study. 
  • Pulmonary emboli 5 days postinjury presenting as fever of unknown origin. 
  • Pulmonary embolism complicating barbiturate overdose. 
  • Pulmonary hemorrhage syndrome as a manifestation of disseminated intravascular coagulation: analysis of ten cases. 
  • Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. 
  • Purpura fulminans. 
  • RNA aptamer to thrombin binds anion-binding exosite-2 and alters protease inhibition by heparin-binding serpins. 
  • RNA aptamers as reversible antagonists of coagulation factor IXa. 
  • Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401 (Alliance). 
  • Randomized comparison of direct thrombin inhibition versus heparin in conjunction with fibrinolytic therapy for acute myocardial infarction: results from the GUSTO-IIb Trial. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO-IIb) Investigators. 
  • Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) trial. 
  • Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. 
  • Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events. 
  • Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. 
  • Rapid assessment of glycoprotein IIb/IIIa blockade with the platelet function analyzer (PFA-100) during percutaneous coronary intervention. 
  • Rapid evaluation of coagulopathies after cardiopulmonary bypass in children using modified thromboelastography. 
  • Re: Nonlocalized lower gastrointestinal bleeding: provocative bleeding studies with intraarterial tPA, heparin, and tolazoline. 
  • Reactivation of ischemic events in acute coronary syndromes: results from GUSTO-IIb. Gobal Use of Strategies To Open occluded arteries in acute coronary syndromes. 
  • Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with acute coronary syndromes. 
  • Recent antiplatelet drug trials in the acute coronary syndromes. Clinical interpretation of PRISM, PRISM-PLUS, PARAGON A and PURSUIT. 
  • Recent trends in the care of patients with non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE initiative. 
  • Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation. 
  • Recognition of heparin-induced thrombocytopenia and initiation of argatroban therapy after cardiothoracic surgery in the intensive care unit. 
  • Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial. 
  • Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. 
  • Reducing cardiac events after acute coronary syndromes. 
  • Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia. 
  • Regional variation across the United States in the management of acute myocardial infarction. GUSTO-1 Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Relation between activated clotting time during angioplasty and abrupt closure. 
  • Relationship between activated clotting time during percutaneous intervention and subsequent bleeding complications. 
  • Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. 
  • Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction: results from the global use of strategies to open occluded arteries in Acute Coronary Syndromes (GUSTO-IIb) trial. 
  • Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. 
  • Response to letters regarding article, “Predictors of outcomes in medically treated patients with acute coronary syndromes after angiographic triage: an Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) substudy”. 
  • Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. 
  • Risk of heparin-induced thrombocytopenia from heparin-bonded vascular prostheses. 
  • Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. 
  • Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention. 
  • Risk stratification in the setting of non-ST elevation acute coronary syndromes 1999-2007. 
  • Risk stratification with a point-of-care cardiac troponin T test in acute myocardial infarction. GUSTOIII Investigators. Global Use of Strategies To Open Occluded Coronary Arteries. 
  • Role for endotoxin and complement in periodontal tissue destruction. 
  • Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. 
  • Role of the gamma-carboxyglutamic acid domain of activated factor X in the presence of calcium during inhibition by antithrombin-heparin. 
  • Roundtable panel discussion: the role of glycoprotein IIb-IIIa receptor inhibitors in acute ischemic coronary syndromes. 
  • Safety and efficacy of bivalirudin monotherapy in patients with diabetes mellitus and acute coronary syndromes: a report from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. 
  • Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. 
  • Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. 
  • Safety and efficacy of switching from unfractionated heparin to bivalirudin during primary percutaneous coronary intervention. 
  • Safety of aprotinin in heparinized and nonheparinized patients. 
  • Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. 
  • Safety of very early sheath removal in patients treated with REG1 for acute coronary syndromes: insights from the RADAR trial. 
  • Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. 
  • Selective O-desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. 
  • Selective infusion of thrombolytic therapy in the acute myocardial infarct-related coronary artery as an alternative to rescue percutaneous transluminal coronary angioplasty. 
  • Sepsis-Induced Coagulopathy and Disseminated Intravascular Coagulation. 
  • Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion. 
  • Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. 
  • Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). 
  • Slowed ST segment recovery despite early infarct artery patency in patients with Q waves at presentation with a first acute myocardial infarction. Implications of initial Q waves on myocyte reperfusion. 
  • Smoking status and outcome after primary coronary angioplasty for acute myocardial infarction. 
  • Society of Cardiovascular Anesthesiologists Clinical Practice Improvement Advisory for Management of Perioperative Bleeding and Hemostasis in Cardiac Surgery Patients. 
  • Standard subcutaneous dosing of unfractionated heparin for venous thromboembolism prophylaxis in surgical ICU patients leads to subtherapeutic factor Xa inhibition. 
  • Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators. 
  • Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. 
  • Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. 
  • Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth. 
  • Structure and function of the glycosaminoglycan binding site of chemokine macrophage-inflammatory protein-1 beta. 
  • Substructure of human von Willebrand factor. Proteolysis by V8 and characterization of two functional domains. 
  • Successful treatment of acute vascular insufficiency in a hand by intra-arterial fibrinolysin, heparin, and reserpine. Case report. 
  • Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. 
  • Sustained ventricular arrhythmias and mortality among patients with acute myocardial infarction: results from the GUSTO-III trial. 
  • Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO Investigators. 
  • Synthesis and evaluation of compounds that facilitate the gastrointestinal absorption of heparin. 
  • Techniques and applications of perioperative therapeutic plasma exchange. 
  • The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa Blockade. 
  • The Effect of Ex Situ Perfusion in a Swine Limb Vascularized Composite Tissue Allograft on Survival up to 24 Hours. 
  • The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. 
  • The Multidimensionality of Cardiovascular Procedures. 
  • The Open (Radial) Artery Hypothesis: How We Can Preserve a Better Arterial Access Site. 
  • The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. 
  • The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21). 
  • The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery. 
  • The complications of brachial arteriotomy. 
  • The determinants of activated partial thromboplastin time, relation of activated partial thromboplastin time to clinical outcomes, and optimal dosing regimens for heparin treated patients with acute coronary syndromes: a review of GUSTO-IIb. 
  • The effect of free fatty acids on insulin-mediated glucose uptake. 
  • The effect of heparin after microsurgical repair in traumatically damaged arteries. 
  • The effect of vascular endothelial growth factor (VEGF) presentation within fibrin matrices on endothelial cell branching. 
  • The effects of MDCO-2010, a serine protease inhibitor, on activated clotting time in blood obtained from volunteers and cardiac surgical patients. 
  • The effects of argatroban on thrombin generation and hemostatic activation in vitro. 
  • The effects of heparin anticoagulants and fill volume in blood gas syringes on ionized calcium and magnesium measurements. 
  • The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. 
  • The force-driven conformations of heparin studied with single molecule force microscopy. 
  • The impact of heparin compounds on cellular inflammatory responses: a construct for future investigation and pharmaceutical development. 
  • The impact of postrandomization crossover of therapy in acute coronary syndromes care. 
  • The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. 
  • The influence of heparin and isoprenaline on the changes produced by pulmonary embolism. 
  • The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a). 
  • The lack of science behind the standard of care. 
  • The phosphorylation of vascular endothelial growth factor receptor-2 (VEGFR-2) by engineered surfaces with electrostatically or covalently immobilized VEGF. 
  • The plasma supplemented modified activated clotting time for monitoring of heparinization during cardiopulmonary bypass: a pilot investigation. 
  • The quality of antiplatelet and anticoagulant medication administration among ST-segment elevation myocardial infarction patients transferred for primary percutaneous coronary intervention. 
  • The risk of major bleeding in patients with suspected heparin-induced thrombocytopenia. 
  • The scientific basis for evaluation and management of thrombotic disorders. 
  • The skin in disseminated intravascular coagulation. Prospective analysis of thirty-six cases. 
  • The vulnerable endothelium: priming the vascular endothelium for thrombosis with unfractionated heparin: biologic plausibility for observations from the Superior Yield of the New Strategy of Enoxaparin, Revascularization and GlYcoprotein IIb/IIIa Inhibitors (SYNERGY) trial. 
  • Therapeutic plasma exchange for management of heparin-induced thrombocytopenia: Results of an international practice survey. 
  • Things I know and things I don't know: how to develop a better opinion. 
  • Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin. 
  • Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Thrombin-Induced Inflammation in Human Decidual Cells Is Not Affected By Heparin. 
  • Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. 
  • Thrombocytopenia in patients with an acute coronary syndrome (from the Global Registry of Acute Coronary Events [GRACE]). 
  • Thrombolysis and adjunctive therapy in acute myocardial infarction: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. 
  • Thrombolytic therapy for myocardial infarction: a perspective of clinical trialists. The GUSTO Investigators. 
  • Thrombosis and ELISA optical density values in hospitalized patients with heparin-induced thrombocytopenia. 
  • Thrombosis during pregnancy and the postpartum period. 
  • Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy. 
  • Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. 
  • Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. 
  • Transesophageal echocardiography before cardioversion. 
  • Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. 
  • Treatment of autochthonous rat brain tumors with steroid plus heparin: a brief report. 
  • Treatment of blister-like aneurysms with the pipeline embolization device. 
  • Treatment of established deep vein thrombosis: a review of the therapeutic armamentarium. 
  • Treatment of mechanical aortic valve thrombosis with heparin and eptifibatide. 
  • Treatment of radiation-induced nervous system injury with heparin and warfarin. 
  • Treatment of recurrent pulmonary embolism by intravenous interruption of the inferior vena cava. 
  • Treatment of sagittal sinus thrombosis associated with cerebral hemorrhage and intracranial hypertension. 
  • Two instruments to determine activated partial thromboplastin time: implications for heparin monitoring. 
  • Two-year outcomes after transcatheter or surgical aortic-valve replacement. 
  • Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. 
  • Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. 
  • Unrelated umbilical cord blood transplantation for an infant with beta-thalassemia major. 
  • Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. 
  • Use of anticoagulant agents and risk of bleeding among patients admitted with myocardial infarction: a report from the NCDR ACTION Registry--GWTG (National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry--Get With the Guidelines). 
  • Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. 
  • Use of fibrin sealant as a hemostatic agent after liver biopsy in swine. 
  • Use of novel preparations of heparin to eliminate interference in ionized calcium measurements: have all the problems been solved? 
  • Use of percutaneously inserted venous catheters in coronary care units. 
  • Use of the REG1 anticoagulation system in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the phase II RADAR-PCI study. 
  • Usefulness of routine unfractionated heparin infusion following primary percutaneous coronary intervention for acute myocardial infarction in patients not receiving glycoprotein IIb/IIIa inhibitors. 
  • Utility of consecutive repeat HIT ELISA testing for heparin-induced thrombocytopenia. 
  • VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF. 
  • Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. 
  • Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. 
  • Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey. 
  • Venous Thromboembolism Prophylaxis For Esophagectomy: A Survey of Practice Patterns Among Thoracic Surgeons. 
  • Venous thromboembolism after hepatic resection: analysis of 5,706 patients. 
  • What is the best anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction? 
  • [Canadian Consensus Conference on Coronary Thrombolysis--current aspects]. 
  • [Livedoid vasculopathy with heterozygous factor V Leiden mutation and sticky platelet syndrome]. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Arepally, Gowthami Morey, Professor of Medicine, Pathology
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Erickson, Harold Paul, James B. Duke Distinguished Professor of Cell Biology, Cell Biology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Hoffman, Maureane, Professor of Pathology, Immunology
  • Krangel, Michael S., George Barth Geller Distinguished Professor of Immunology, Immunology
  • Laskowitz, Daniel Todd, Professor of Neurology, Duke Innovation & Entrepreneurship
  • Milano, Carmelo Alessio, Professor of Surgery, Surgery, Cardiovascular and Thoracic Surgery
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. Distinguished Professor, Medicine, Clinical Pharmacology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics